Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3337861
Max Phase: Preclinical
Molecular Formula: C38H44N4O
Molecular Weight: 572.80
Molecule Type: Small molecule
Associated Items:
ID: ALA3337861
Max Phase: Preclinical
Molecular Formula: C38H44N4O
Molecular Weight: 572.80
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CC[C@@H]1CN2CC[C@@]34c5ccccc5N5/C=C6/[C@H]7C[C@@H]8N(CC[C@@]89c8ccccc8N(/C=C(/[C@H]1C[C@H]23)[C@H]54)[C@@H]69)C[C@H]7CCO
Standard InChI: InChI=1S/C38H44N4O/c1-2-23-19-39-14-12-37-29-7-3-6-10-32(29)42-22-28-26-18-34-38(13-15-40(34)20-24(26)11-16-43)30-8-4-5-9-31(30)41(36(28)38)21-27(35(37)42)25(23)17-33(37)39/h3-10,21-26,33-36,43H,2,11-20H2,1H3/b27-21-,28-22-/t23-,24-,25+,26+,33+,34+,35+,36+,37-,38-/m1/s1
Standard InChI Key: QAVRQLXVMMTXOP-NILLWRJDSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 572.80 | Molecular Weight (Monoisotopic): 572.3515 | AlogP: 5.26 | #Rotatable Bonds: 3 |
Polar Surface Area: 33.19 | Molecular Species: BASE | HBA: 5 | HBD: 1 |
#RO5 Violations: 2 | HBA (Lipinski): 5 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: | CX Basic pKa: 10.90 | CX LogP: 4.37 | CX LogD: -1.60 |
Aromatic Rings: 2 | Heavy Atoms: 43 | QED Weighted: 0.54 | Np Likeness Score: 1.20 |
1. Zlotos DP, Tränkle C, Holzgrabe U, Gündisch D, Jensen AA.. (2014) Semisynthetic analogues of toxiferine I and their pharmacological properties at α7 nAChRs, muscle-type nAChRs, and the allosteric binding site of muscarinic M2 receptors., 77 (9): [PMID:25192059] [10.1021/np500259j] |
Source(1):